Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
Andrea Ellis, a director at BridgeBio Pharma, Inc. (NASDAQ:BBIO), recently sold 30,000 shares of the company’s common stock on April 1, 2025. The shares were sold at an average price of $34.05 each, amounting to a total sale value of approximately $1.02 million. This transaction was part of a predetermined trading plan under Rule 10b5-1, adopted by Ellis on December 30, 2024. The sale comes as BridgeBio’s stock has shown strong momentum, with a 35% gain over the past six months, according to InvestingPro data.
On the same day, Ellis also exercised stock options to acquire 30,000 shares at a price of $8.45 per share, which were then sold. Following these transactions, Ellis holds 12,000 shares of BridgeBio Pharma directly. With a market capitalization of $6.5 billion, BridgeBio has attracted significant analyst attention, with targets ranging from $36 to $95 per share. InvestingPro subscribers can access detailed analysis and 6 additional key insights about the company’s financial health and growth prospects.
These transactions highlight Ellis’s active management of her holdings in BridgeBio Pharma, a company based in Palo Alto, California, that is engaged in pharmaceutical preparations. The company maintains strong liquidity with a current ratio of 4.67, though it currently operates at a loss with negative earnings per share of $2.88 over the last twelve months.
In other recent news, BridgeBio Pharma announced significant clinical advancements for its drug acoramidis, following a Phase 3 ATTRibute-CM trial. The drug showed a statistically significant benefit in reducing all-cause mortality and first cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy. Additionally, the Japanese Ministry of Health, Labour and Welfare approved acoramidis, marketed as Beyonttra, for treating ATTR-CM, highlighting its potential to reduce cardiovascular events. This approval will result in a $30 million milestone payment to BridgeBio from Alexion (NASDAQ:ALXN), AstraZeneca (NASDAQ:AZN) Rare Disease, and the company will also earn royalties on sales in Japan.
Raymond (NSE:RYMD) James maintained its Outperform rating and $57 price target for BridgeBio, citing favorable data from the American College of Cardiology annual meeting that supports acoramidis’s competitive profile. Redburn-Atlantic initiated coverage on BridgeBio with a Buy rating and a $50 price target, noting the rapid progress of the Attruby rollout as a key growth driver. The firm expects earnings to remain negative until 2028 due to ongoing pipeline investments, but sees potential for medium-term top-line growth. These developments reflect BridgeBio’s strategic focus on addressing unmet medical needs in genetic diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.